1. Flatten G, Jünger S, Gunkel S, Singh J, Petzold E. [Traumatic and psychosocial distress in patients with acute tumors]. Psychother Psychosom Med Psychol. 2003;53(3-4):191-201.
2. Kim GM, Kim SJ, Song SK, Kim HR, Kang BD, Noh SH, et al. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. BMC Cancer. 2017;17(1):283.
3. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. The Lancet Oncology. 2011;12(2):160-74.
4. Joshy G, Thandrayen J, Koczwara B, Butow P, Laidsaar-Powell R, Rankin N, et al. Disability, psychological distress and quality of life in relation to cancer diagnosis and cancer type: population-based Australian study of 22,505 cancer survivors and 244,000 people without cancer. BMC Med. 2020;18(1):372-.
5. Grassi L, Fujisawa D, Odyio P, Asuzu C, Ashley L, Bultz B, et al. Disparities in psychosocial cancer care: a report from the International Federation of Psycho-oncology Societies. Psychooncology. 2016;25(10):1127-36.
6. Fann JR, Ell K, Sharpe M. Integrating psychosocial care into cancer services. J Clin Oncol. 2012;30(11):1178-86.
7. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. The New England journal of medicine. 2010;363(8):733-42.
8. Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet. 2014;383(9930):1721-30.
9. Choi JY, Kong KA, Chang YJ, Jho HJ, Ahn EM, Choi SK, et al. Effect of the duration of hospice and palliative care on the quality of dying and death in patients with terminal cancer: A nationwide multicentre study. European journal of cancer care. 2018;27(2):e12771.
10. Shin JA, Parkes A, El-Jawahri A, Traeger L, Knight H, Gallagher ER, et al. Retrospective evaluation of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer. Palliative medicine. 2016;30(9):854-61.
11. Parajuli J, Tark A, Jao YL, Hupcey J. Barriers to palliative and hospice care utilization in older adults with cancer: A systematic review. Journal of geriatric oncology. 2020;11(1):8-16.
12. Wedding U, Meran JG, Höffken K. Übertherapie in der Onkologie: Wann ist weniger mehr? Der Onkologe. 2008;14(7):691-700.
13. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616-25.
14. Radbruch L, Payne S. Standards und Richtlinien für Hospiz- und Palliativversorgung in Europa: Teil 2. Zeitschrift für Palliativmedizin. 2011;12:260-70.
15. Cuthbert CA, Boyne DJ, Yuan X, Hemmelgarn BR, Cheung WY. Patient-reported symptom burden and supportive care needs at cancer diagnosis: a retrospective cohort study. Support Care Cancer. 2020;28(12):5889-99.
16. Dougherty M. Assessment of patient and family needs during an inpatient oncology experience. Clin J Oncol Nurs. 2010;14(3):301-6.
17. Berezowska A, Passchier E, Bleiker E. Evaluating a professional patient navigation intervention in a supportive care setting. Support Care Cancer. 2019;27(9):3281-90.
18. Porzig R, Neugebauer S, Heckmann T, Adolf D, Kaskel P, Froster UG. Evaluation of a cancer patient navigation program ("Onkolotse") in terms of hospitalization rates, resource use and healthcare costs: rationale and design of a randomized, controlled study. BMC Health Serv Res. 2018;18(1):413.
19. Wagner EH, Ludman EJ, Aiello Bowles EJ, Penfold R, Reid RJ, Rutter CM, et al. Nurse navigators in early cancer care: a randomized, controlled trial. J Clin Oncol. 2014;32(1):12-8.
20. Skrutkowski M, Saucier A, Eades M, Swidzinski M, Ritchie J, Marchionni C, et al. Impact of a pivot nurse in oncology on patients with lung or breast cancer: symptom distress, fatigue, quality of life, and use of healthcare resources. Oncol Nurs Forum. 2008;35(6):948-54.
21. Tho PC, Ang E. The effectiveness of patient navigation programs for adult cancer patients undergoing treatment: a systematic review. JBI Database System Rev Implement Rep. 2016;14(2):295-321.
22. Hendren S, Griggs JJ, Epstein R, Humiston S, Jean-Pierre P, Winters P, et al. Randomized controlled trial of patient navigation for newly diagnosed cancer patients: effects on quality of life. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1682-90.
23. Fiscella K, Whitley E, Hendren S, Raich P, Humiston S, Winters P, et al. Patient Navigation for Breast and Colorectal Cancer Treatment: A Randomized Trial. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1673-81.
24. Frick J, Schindel D, Gebert P, Grittner U, Schenk L. Improving quality of life in cancer patients through higher participation and health literacy: study protocol for evaluating the oncological social care project (OSCAR). BMC Health Services Research. 2019;19(1):754.
25. Harrison JD, Solomon MJ, Young JM, Meagher A, Hruby G, Salkeld G, et al. Surgical and oncology trials for rectal cancer: Who will participate? Surgery. 2007;142(1):94-101.e20.
26. Gollhofer SM, Wiskemann J, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, et al. Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy. BMC Cancer. 2015;15(1):186.
27. Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, et al. Barriers to Clinical Trial Participation by Older Women With Breast Cancer. Journal of Clinical Oncology. 2003;21(12):2268-75.
28. Puts MTE, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, et al. A systematic review of factors influencing older adults’ decision to accept or decline cancer treatment. Cancer Treatment Reviews. 2015;41(2):197-215.
29. Wright JR, Whelan TJ, Schiff S, Dubois S, Crooks D, Haines PT, et al. Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision. Journal of Clinical Oncology. 2004;22(21):4312-8.
30. Senn S. Testing for baseline balance in clinical trials. Stat Med. 1994;13(17):1715-26.
31. Kahan BC, Jairath V, Doré CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15:139.
32. Karrison T, Kocherginsky M. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clinical Trials. 2018;15(2):178-88.
33. Nohr EA, Liew Z. How to investigate and adjust for selection bias in cohort studies. Acta Obstetricia et Gynecologica Scandinavica. 2018;97(4):407-16.
34. Harvey RA, Hayden JD, Kamble PS, Bouchard JR, Huang JC. A comparison of entropy balance and probability weighting methods to generalize observational cohorts to a population: a simulation and empirical example. Pharmacoepidemiology and Drug Safety. 2017;26(4):368-77.
35. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-107.
36. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85(5):365-76.
37. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, D. C, Bottomley A, et al. The EORTC QLQ-C30 Scoring Manual (3rd Edition). 2001.
38. Lorini C, Santomauro F, Grazzini M, Mantwill S, Vettori V, Lastrucci V, et al. Health literacy in Italy: a cross-sectional study protocol to assess the health literacy level in a population-based sample, and to validate health literacy measures in the Italian language. BMJ Open. 2017;7(11):e017812.
39. Brenk-Franz K, Hunold G, Galassi JP, Tiesler F, Herrmann W, Freund T, et al. Quality of the physician-patient relationship - Evaluation of the German version of the Patient Reactions Assessment (PRA-D). 2016;92:103-8.
40. Harter M, Simon D, Kriston L. [The German modified version of the Autonomy Preference Index (API-Dm)]. Klin Diagn Eval. 2011;4(1E):5-14.
41. O'Connor AM. User Manual - Decisional Conflict Scale [Update 2010]. In: Institute OHR, editor. 1993.
42. Gaab J, Latanzia-Bunschoten S, Sprott H. Illness Perception Questionnaire. In: Begel, Wirtz, Zwingmann, editors. Kompendium: Diagnostische Verfahren in der Rehabilitation. Göttingen: Hogrefe Verlag; 2008.
43. Rattay P, Butschalowsky H, Rommel A, Prütz F, Jordan S, Nowossadeck E, et al. [Utilization of outpatient and inpatient health services in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5-6):832-44.
44. Kocalevent R-D, Berg L, Beutel ME, Hinz A, Zenger M, Härter M, et al. Social support in the general population: standardization of the Oslo social support scale (OSSS-3). BMC Psychology. 2018;6(1):31.
45. Hoebel J, Müters S, Kuntz B, Lange C, Lampert T. [Measuring subjective social status in health research with a German version of the MacArthur Scale]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015;58(7):749-57.
46. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37(11):1345-51.
47. Hinz A, Singer S, Brähler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncologica. 2014;53(7):958-65.
48. Steffen McLouth LE, Lycan TW, Jr., Levine BJ, Gabbard J, Ruiz J, Farris M, et al. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. Clinical lung cancer. 2019.
49. Hinz A, Mehnert A, Dégi C, Reissmann DR, Schotte D, Schulte T. The relationship between global and specific components of quality of life, assessed with the EORTC QLQ-C30 in a sample of 2019 cancer patients. European journal of cancer care. 2017;26(2).
50. Verkissen MN, Hjermstad MJ, Van Belle S, Kaasa S, Deliens L, Pardon K. Quality of life and symptom intensity over time in people with cancer receiving palliative care: Results from the international European Palliative Care Cancer Symptom study. PloS one. 2019;14(10):e0222988.
51. Linder SK, Swank PR, Vernon SW, Mullen PD, Morgan RO, Volk RJ. Validity of a low literacy version of the Decisional Conflict Scale. Patient Education and Counseling. 2011;85(3):521-4.
52. Colombet I, Rigal L, Urtizberea M, Vinant P, Rouquette A. Validity of the French version of the Autonomy Preference Index and its adaptation for patients with advanced cancer. PLOS ONE. 2020;15(1):e0227802.
53. Pelikan J, Röthlin F, Ganahl K, Boltzmann L. Measuring comprehensive health literacy in general populations: validation of instrument, indices and scales of the HLS-EU study. 2014.
54. Al-Refaie WB, Vickers SM, Zhong W, Parsons H, Rothenberger D, Habermann EB. Cancer Trials Versus the Real World in the United States. Annals of Surgery. 2011;254(3).
55. Cottin V, Arpin D, Lasset C, Cordier JF, Brune J, Chauvin F, et al. Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole. Annals of Oncology. 1999;10(7):809-16.
56. Bubis LD, Davis L, Mahar A, Barbera L, Li Q, Moody L, et al. Symptom Burden in the First Year After Cancer Diagnosis: An Analysis of Patient-Reported Outcomes. J Clin Oncol. 2018;36(11):1103-11.
57. Hoffmann F, Icks A. [Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor]. Gesundheitswesen. 2012;74(5):291-7.
58. Werner A, Reitmeir P, John J. [Switching sickness funds and risk compensation mechanisms in the statutory health insurance system in Germany--empirical results from the cooperative health research in the region of Augsburg (KORA)]. Gesundheitswesen. 2005;67 Suppl 1:S158-66.
59. Hartung TJ, Johansen C. Sozioökonomischer Status und Krebs. Forum. 2017;32(4):318-23.
60. Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. The Lancet Oncology. 2015;16(1):e32-e42.
61. Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. Social Science & Medicine. 2018;210:2-21.
62. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014(4):Mr000034.
63. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-81.
64. Deb S, Austin PC, Tu JV, Ko DT, Mazer CD, Kiss A, et al. A Review of Propensity-Score Methods and Their Use in Cardiovascular Research. The Canadian journal of cardiology. 2016;32(2):259-65.
65. Elze MC, Gregson J, Baber U, Williamson E, Sartori S, Mehran R, et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. Journal of the American College of Cardiology. 2017;69(3):345-57.
66. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in Medicine. 2015;34(28):3661-79.